RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small‑molecule drugs that modulate the immune system to treat inflammatory diseases and cancer. The company applies immunology insights, structure‑based design, and medicinal chemistry to identify selective modulators of key immune pathways.
Its pipeline has included investigational candidates such as RPT193, an oral CCR4 antagonist being studied for atopic dermatitis and other allergic inflammatory conditions, and FLX475, a selective CCR4 antagonist evaluated in oncology, including in combination with checkpoint inhibitors, to reduce immunosuppressive regulatory T cells in the tumor microenvironment. RAPT is headquartered in South San Francisco, California, USA.
None yet. When a new project in the record names RAPT Therapeutics as owner, partner or investor, it shows here.
GSK acquires ozureprubart, a potential long-acting anti-IgE therapy for food allergies, with phase IIb data expected in 2027. The deal is valued at $2.2 billion.
